A methodological quality review of citations of randomized controlled trials of diabetes type2 in leading clinical practice guidelines and systematic reviews
Authors:
- Azadeh AletahaAAAzadeh Aletaha
- Mohammad-Reza MalekpourMMMohammad-Reza Malekpour
- Abbas Ali KeshtkarAKAbbas Ali Keshtkar
- Hamid Reza BaradaranHBHamid Reza Baradaran
- Shahram SedghiSSShahram Sedghi
- Yasaman MansooriYMYasaman Mansoori
- Mehdi HajianiMHMehdi Hajiani
- Somayeh DelavariSDSomayeh Delavari
- Farzaneh HabibiFHFarzaneh Habibi
- Maryam RazmgirMRMaryam Razmgir
- Saeedeh SaeediSSSaeedeh Saeedi
- Akbar SoltaniASAkbar Soltani
- 19 October 2023
- journal article
- review article
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (1) , 101-114
Abstract
Objective Evaluate methodological quality of type 2 diabetes RCTs conducted in Iran and cited in clinical practice guidelines and systematic reviews and meta-analyses. Methods We conducted a descriptive methodological quality review, analyzing 286 Randomized Controlled Trials (RCTs) on diabetes mellitus published in Iran from July 2004 to 2021. We searched six databases systematically and evaluated eligible articles using the CONSORT 2010 checklist for abstracts. Two investigators assessed the data using a 17-item checklist derived from CONSORT. Additionally, we examined the citations of each RCT in 260 clinical practice guidelines, with a specific focus on the adequate reporting of outcomes. Results Out of 6667 articles, 286 analyzed. Poor reporting and failure to meet criteria observed. Only 3.8% cited in guidelines. Reporting rates: primary outcomes (41.9%), randomization (61.8%), trial recruitment (12.6%), blinding (50.8%). 27.9% cited in systematic reviews, 50.34% in systematic reviews and meta-analyses, 26.57% in meta-analyses. 67.8% of papers cited in systematic reviews. Adherence highest for participants, objective, randomization, intervention, outcome; lowest for recruitment, trial design, funding source, harms, and reporting primary outcomes. Conclusions Poor methodological reporting and adherence to CONSORT checklist in evaluated RCTs, especially in methodological sections. Improvements needed for reliable and applicable results in guidelines, reviews, and meta-analyses. Inadequate outcome reporting challenges researchers, clinicians, and policymakers, impacting evidence-based decision-making. Urgent improvements in RCT registration necessary.Keywords
This publication has 47 references indexed in Scilit:
- Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane reviewaSystematic Reviews, 2012
- Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journalsCochrane Database of Systematic Reviews, 2012
- CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trialsInternational Journal of Surgery, 2012
- The Levels of Evidence and Their Role in Evidence-Based MedicinePlastic and Reconstructive Surgery, 2011
- Daily consumption of vitamin D– or vitamin D + calcium–fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trialThe American Journal of Clinical Nutrition, 2011
- Effects of the Dietary Approaches to Stop Hypertension (DASH) Eating Plan on Cardiovascular Risks Among Type 2 Diabetic PatientsDiabetes Care, 2010
- Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic ReviewDiabetes Care, 2010
- Comparison of Registered and Published Primary Outcomes in Randomized Controlled TrialsJAMA, 2009
- Do Guidelines for the Diagnosis and Monitoring of Diabetes Mellitus Fulfill the Criteria of Evidence-Based Guideline Development?Clinical Chemistry, 2008
- CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and ElaborationPLOS Medicine, 2008